Concert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata
THRIVE-AA1 Study Meets Primary Endpoint for Scalp Hair Regrowth and Key Secondary Endpoints at Both Doses Statistically Significant Hair Regrowth Observed as Early as Eight Weeks CTP-543 Has Potential to be Best-in-Class for the Treatment of Alopecia Areata Topline Data from Second Phase 3 Trial, THRIVE-AA2, Expected Third Quarter of 2022 LEXINGTON, Mass.–(BUSINESS WIRE)–$CNCE #AlopeciaAreata—Concert … [Read more…]
